Payment overview · 2025
General Payments
$1,919.07
37 reported records · 12 companies
Healthcare provider profile · identity verified
Leslie D. Ward, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1861695132
Verified facts
What the public records show
CMS Open Payments records show Leslie D. Ward, M.D. received $1,919.07 in general payments during 2025 across 37 reported records.
Gilead Sciences, Inc. accounted for 70.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Epclusa as an associated drug or biological on 4711 records involving 2021 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Epclusa by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $1,352.96 | 70.5% | 10 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $201.48 | 10.5% | 9 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $87.57 | 4.6% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.08 | 4.0% | 3 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $40.16 | 2.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $35.12 | 1.8% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.23 | 1.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $27.81 | 1.4% | 1 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $21.60 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.50 | 0.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $14.88 | 0.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $13.68 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $1,090.00 | 1 |
| Food and Beverage | $829.07 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $1,239.32 | 3 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $122.41 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $87.57 | 5 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $79.07 | 7 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $40.16 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.63 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $27.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $13.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 67 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Epclusa open payments reported associated product |
CMS Open Payments — General Payments 4711 supporting records · 2021 recipient NPIs · example record 1234350832 |
Epclusa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 192 | 42 |
| Omeprazole | Omeprazole | 155 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 111 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 98 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 97 | 23 |
| Lisinopril | Lisinopril | 88 | 25 |
| Levothyroxine Sodium | Levothyroxine Sodium | 79 | 24 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 67 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 19 |
| Trazodone Hcl | Trazodone Hcl | 67 | 18 |
| Metformin Hcl | Metformin Hcl | 66 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 60 | 20 |
| Furosemide | Furosemide | 58 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 23 |
| Buspirone Hcl | Buspirone Hcl | 57 | 14 |
| Sertraline Hcl | Sertraline Hcl | 55 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 13 |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 42 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 41 | 12 |
| Meloxicam | Meloxicam | 40 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 11 |
| Atenolol | Atenolol | 35 | suppressed |
| Celecoxib | Celecoxib | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Allopurinol | Allopurinol | 33 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 26 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Losartan Potassium | Losartan Potassium | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Ozempic | Semaglutide | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Latanoprost | Latanoprost | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Clonazepam | Clonazepam | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Epclusa | Sofosbuvir/Velpatasvir | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,919.07 · 37 records | Gilead Sciences, Inc. | BEYFORTUS, Biktarvy, CABENUVA, CAPLYTA, Cologuard Collection Kit, DOVATO, INVEGA SUSTENNA, JOURNAVX, MAVYRET, QULIPTA, Qelbree, TONMYA, UBRELVY, WaveWriter Alpha Prime 16 | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error